sylvie bonvalot(@SBonvalot) 's Twitter Profileg
sylvie bonvalot

@SBonvalot

MD, PHD, HDR Head Sarcoma Surgery Institut Curie Paris

ID:1137028048442802176

calendar_today07-06-2019 16:06:26

56 Tweets

750 Followers

144 Following

Follow People
sylvie bonvalot(@SBonvalot) 's Twitter Profile Photo

'Diagnostic accuracy and safety of percutaneous core needle biopsy of retroperitoneal tumours' (via ) ncbi.nlm.nih.gov/pubmed/38086314

account_circle
Alessandro Gronchi(@alegronchi) 's Twitter Profile Photo

TARPSWG 10th yr anniversary. Who could have guessed back then how much we would have been able to achieve? Hundreds of members for multiple countries and 5 continents! And an observational study with thousands of pts in it! CTOS Society of Surgical Oncology European Society of Surgical Oncology (ESSO) EORTC

@TARPSWG 10th yr anniversary. Who could have guessed back then how much we would have been able to achieve? Hundreds of members for multiple countries and 5 continents! And an observational study with thousands of pts in it! @ctosociety @SocSurgOnc @ESSOnews @EORTC
account_circle
Roberto Pestana, MD(@PestanaRC) 's Twitter Profile Photo

Very interesting - and persuasive- presentation by sylvie bonvalot

Interestingly, numbers to define “high-volume” centers are tipically lower than would be anticipated

CTOS

Very interesting - and persuasive- presentation by @SBonvalot Interestingly, numbers to define “high-volume” centers are tipically lower than would be anticipated #CTOS2023 @ctosociety
account_circle
Liz Connolly(@DrLizConnolly) 's Twitter Profile Photo

LMS-04:
▫️DOX v DOX & trabectedin with ongoing TRAB
▫️Randomised ph3, n=150
▫️Updated results at

⭐️Improved PFS1, PFS2, OS ⭐️

▪️RR before surg 13% v 36%
🔹more surgery in DOX+TRAB

▪️PFS 6.21 v 12.19m
▪️2 yr PFS 2.7 v 30.2%

🔸OS 23.78 v 33.08m
🔸2yr OS 49 v 69%

LMS-04: ▫️DOX v DOX & trabectedin with ongoing TRAB ▫️Randomised ph3, n=150 #LMS ▫️Updated results at #ESMO23 ⭐️Improved PFS1, PFS2, OS ⭐️ ▪️RR before surg 13% v 36% 🔹more surgery in DOX+TRAB ▪️PFS 6.21 v 12.19m ▪️2 yr PFS 2.7 v 30.2% 🔸OS 23.78 v 33.08m 🔸2yr OS 49 v 69%
account_circle
Liz Connolly(@DrLizConnolly) 's Twitter Profile Photo

Surgical, med onc and rad onc perspectives on hereditary syndromes in
by sylvie bonvalot WinetteVanDerGraaf Beate Timmerman

Really excellent session, panel and discussions at 🙏👏

Surgical, med onc and rad onc perspectives on hereditary syndromes in #sarcoma by @SBonvalot @Winette_vdGraaf Beate Timmerman Really excellent session, panel and discussions at #ESMO23🙏👏
account_circle
Institut Curie(@institut_curie) 's Twitter Profile Photo

🔶 Beyond study results, @Institut_Curie's physicians also share their expertise through Special Sessions at , as:
➡️ Prof. Anne Vincent-Salomon, discussing in cancer prognosis
➡️ Prof. sylvie bonvalot, about treatment of sarcoma pts w/genetic predisposition

🔶 Beyond study results, @Institut_Curie's physicians also share their expertise through Special Sessions at #ESMO23, as: ➡️ Prof. @AVincentSalomon, discussing #ArtificialIntelligence in cancer prognosis ➡️ Prof. @SBonvalot, about treatment of sarcoma pts w/genetic predisposition
account_circle
sylvie bonvalot(@SBonvalot) 's Twitter Profile Photo

'Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial' (via ) ncbi.nlm.nih.gov/pubmed/37777684

account_circle
sylvie bonvalot(@SBonvalot) 's Twitter Profile Photo

Interesting article 'Percutaneous Uterine Needle Biopsy with Microscopic and Array-CGH Analyses for Preoperative Sarcoma Diagnosis in Patients with Suspicious Myometrial Tumors on MRI: A Prospective Pilot Study (SARCGYN)' (via ) ncbi.nlm.nih.gov/pubmed/36287348

account_circle
ASTRO(@ASTRO_org) 's Twitter Profile Photo

In the : Final safety and HRQoL results of the phase II/III Act.In.Sarc study with preoperative NBTXR3 plus radiotherapy versus radiotherapy in locally advanced soft-tissue sarcoma ➡️ sylvie bonvalot bit.ly/Bonvalot2022

In the #RedJournal: Final safety and HRQoL results of the phase II/III Act.In.Sarc study with preoperative NBTXR3 plus radiotherapy versus radiotherapy in locally advanced soft-tissue sarcoma ➡️ @SBonvalot bit.ly/Bonvalot2022
account_circle